Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Unmet Need for Massive Transfusion in Indian Trauma Patients

18 febbraio 2020 aggiornato da: Martin Gerdin, Karolinska Institutet

What is the Difference Between Predicted Need for Massive Transfusion and Actual Transfusion in Adult Trauma Patients in an Urban Indian Setting?

This study aims to estimate the difference between predicted and provided massive transfusion in adult trauma patients admitted to university hospitals in urban India.

Panoramica dello studio

Stato

Completato

Condizioni

Intervento / Trattamento

Descrizione dettagliata

Background

Trauma fatalities account for 9 % of the world's deaths, superseding the number of deaths caused by HIV/AIDS, tuberculosis and malaria combined, disproportionately affecting low- and middle-income countries (LMIC). Hemorrhage is one of the leading causes of preventable death among trauma patients. Up to 5 % of trauma patients require massive transfusions (MT), defined as administration of ten or more units of packed red blood cells (PRBC) within 24 hours of injury.

India is an LMIC lacking structured trauma care systems and where blood products remain a scarce commodity. There is a sizeable gap in supply and demand as India lacks about four million units of blood per year according to World Health Organization estimates. The in-hospital mortality in an urban Indian trauma setting has been found to be twice that of high-income equivalents and inadequate resuscitation and bleeding control of hemorrhaging patients has been found to be the main cause of preventable deaths.

Considering the general lack of blood components in India it is reasonable to assume that there is an unmet need of blood transfusions in trauma patients as well. The extent of the potentially unmet need of MT constitutes a major gap of knowledge and also an important basis for resource allocation and development of MT protocols suited for local needs, hence our research question: what is the difference between predicted need for MT and actual transfusion in an urban Indian trauma setting?

Aim

To estimate the difference between predicted need for MT and provided MT in adult trauma patients in an urban Indian setting. The hypothesis is that there will be a substantial discrepancy between predicted need and provided MT, indicating an unmet need of blood transfusions.

Study design

A retrospective analysis of the Towards Improved Trauma Outcomes in India (TITCO) cohort will be conducted.

Setting

The TITCO dataset includes 16,047 patients enrolled between July 2013 and December 2015 from four public university hospitals, namely the King Edward Memorial Hospital and Lokmanya Tilak Municipal General Hospital in Mumbai, Jai Prakash Narayan Apex Trauma Center in New Delhi and the Seth Sukhlal Karnani Memorial Hospital in Kolkata. These hospitals are characterized by nominal patient fees and all operate trauma units.

An externally employed and trained data collector working eight-hour shifts in each facility gathered patient data in a prospective observational fashion, rotating between day, evening and night shifts. Data from patients admitted outside of these hours was retrieved retrospectively within days of admission. The patients were followed until discharge or death, whichever occurred first.

Source and method of participant selection

Participants were selected consecutively during the study period according to the aforementioned eligibility criteria, either via direct observation during the data collector's shift or through retrospective data retrieval from patient records.

Covariates

To estimate the proportion of patients predicted to need MT the Assessment of Blood Consumption (ABC) score will be used. The rationale for using the ABC score in this context is that it is based on routinely recorded vital signs and examination results that are all available in TITCO, unlike other scores that also require laboratory results. Further, the intent is not to validate the score, but to use it as an informed basis for identifying patients with substantial bleeding. ABC is based on four dichotomous non-laboratory parameters that are readily available in the early assessment phase.

Penetrating mechanism (0=no, 1=yes)

Arrival Systolic Blood Pressure <= 90 mm Hg (0=no, 1=yes)

Arrival Heart Rate >= 120 bpm (0=no, 1=yes)

Positive focused assessment sonography for trauma (FAST) (0=no, 1=yes)

A score of two or more has been set to indicate need for MT. Age, sex, and mechanism of injury in addition to the variables included in the ABC score will be presented to characterize the study sample.

Data sources/measurement

Where FAST recording in the study sample is not reported as "positive" relevant free text terms will be used to find indications of free fluid in abdomen, pelvis or pericardium. Where FAST recording is missing relevant ICD-10 codes will be used for screening the free text variables reporting computer tomography (CT) and intraoperative findings.

The proportion of patients predicted to need MT (a) will be estimated by dividing the number of patients with an ABC score of two or more by the total number of patients in the study sample. The proportion of actual MT received (b) will then be calculated by dividing the number of patients who received ten or more units of PRBC with the total number of patients with complete clinical data.

Bias

The data collectors were externally trained and funded by project management. The data was obtained through direct observation and retrieval from patient records without interference in clinical work. All data collectors had at least a health science master's degree and were continuously trained and supervised by project management. The collected data is multi-institutional, likely reducing the effects of highly operator and setting dependent variables.

Injury severity bias due to missing data from severely injured patients is a recognized problem in trauma registries and to counteract this it is imperative to account for as many patients as possible using alternatives for the FAST positive variable that would indicate ongoing intra-abdominal, pericardial or pelvic hemorrhage. However, the approach of using surrogates for FAST may also yield misleading results due to overestimation. To estimate the magnitude of this source of bias a sensitivity analysis will be conducted.

In addition, the ABC score was originally developed and validated in a high-income setting with a likelihood of differing demography and patterns of injury mechanism, possibly yielding results not representable of true MT needs in our study population. However, in this case the ABC score will rather be used as a tool for the estimation of blood needs rather than as a prediction tool or aid in clinical decision-making.

Study size

Based on previous research it is assumed that 10% of patients will be predicted to need MT. In contrast, based on clinical experience from the study setting, it is assumed that a maximum of 5% received it. Assuming that 10 % (~ 1600 patients) will be predicted to need an MT and 5 % (~ 800 patients) received it then the sample size based on a two-sided paired comparison of proportions, i.e. two-sided McNemar's test, needed to detect this difference with 80% power is 369 patients, setting alpha to 5% and beta to 20%. In other words, because all complete observations in the cohort will be analyzed, it can safely be said that this study is powered to detect this difference at the 80% level.

Quantitative variables

When characterizing the study sample, all quantitative variables will be presented as continuous. In the calculation of the ABC score the quantitative variables arrival heart rate and arrival systolic blood pressure will be dichotomized as detailed in the covariate section above.

Statistical methods

All statistical analyses will be performed in R, a free open-source software for statistical computing and graphics. Qualitative sample characteristics will be presented using number and percentage whereas quantitative sample characteristics will be presented as median, values at the 25th and 75th percentile, as well as minimum and maximum values.

The main analysis is a complete case analysis where observations with missing covariate values will be excluded. Depending on the amount of missingness, multiple imputation using chained equations might be used to handle missing data. The main analysis will thereafter be conducted in two steps. First, the proportion of patients with an ABC score ≥ 2, i.e. patients with predicted need of MT will be calculated. Thereafter the proportion of patients who actually received MT (b) will be calculated based on transfusion data in the TITCO registry. The outcome is defined as the difference between the proportion of adult patients predicted to receive MT and the proportion of patients who did receive MT.

Sensitivity analyses

Based on clinical experience in this particular setting a sensitivity analysis will be conducted with a cutoff value of 4 units of PRBCs in 24 hours for the definition of MT. A sensitivity analysis will also be conducted by restricting the analysis to FAST positive patients where coding using CT or intraoperative findings was not used.

Tipo di studio

Osservativo

Iscrizione (Effettivo)

16047

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

15 anni e precedenti (Bambino, Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

Adult trauma patients

Descrizione

Inclusion Criteria:

  • Presented alive
  • History of trauma
  • ≥ 15 years old

Exclusion Criteria:

  • Burn
  • Missing data on outcome or covariates

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Modelli osservazionali: Coorte
  • Prospettive temporali: Retrospettiva

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Lasso di tempo
The difference between the proportions of adult patients predicted to receive MT and patients who did receive MT.
Lasso di tempo: ≤ 24 hours within arrival
≤ 24 hours within arrival

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

1 gennaio 2017

Completamento primario (Effettivo)

31 dicembre 2018

Completamento dello studio (Effettivo)

31 dicembre 2018

Date di iscrizione allo studio

Primo inviato

26 febbraio 2017

Primo inviato che soddisfa i criteri di controllo qualità

26 febbraio 2017

Primo Inserito (Effettivo)

1 marzo 2017

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

20 febbraio 2020

Ultimo aggiornamento inviato che soddisfa i criteri QC

18 febbraio 2020

Ultimo verificato

1 febbraio 2020

Maggiori informazioni

Termini relativi a questo studio

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • ruut-seger-201702262039

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

No

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su Nessun intervento

3
Sottoscrivi